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Gadolinium (Gd) based contrast agents (GBCAs) in magnetic
resonance imaging (MRI) are used in daily clinical practice and
appear safe in most patients; however, nephrogenic systemic
fibrosis (NSF) is a recently recognized severe complication
associated with GBCAs. It affects primarily patients with renal
disease, such as stage 4 or 5 chronic kidney disease (CKD;
glomerular filtration rate o30 ml/min per 1.73 m2), acute
kidney injury, or kidney and liver transplant recipients with
kidney dysfunction. Contrast-enhanced MRI and computed
tomography (CT) scans provide important clinical information
and influence patient management. An alternative contrast
agent is needed to obtain adequate imaging results while
avoiding the risk of NSF in this vulnerable patient group. One
potential alternative is ultrasmall superparamagnetic iron
oxide (USPIO) nanoparticles, which provide enhancement
characteristics similar to GBCAs. We review our experience in
approximately 150 patients on the potential benefits of the
USPIOs ferumoxtran-10 and ferumoxytol. We focus on central
nervous system (CNS) MRI but also review imaging of other
vascular beds. Safety studies, including USPIO administration
(ferumoxytol) as iron supplement therapy in CKD patients on
and not on dialysis, suggest that decreased kidney function
does not alter the safety profile. We conclude that for both
CNS MR imaging and MR angiography, USPIO agents like
ferumoxytol are a viable option for patients at risk for NSF.
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The administration of gadolinium (Gd)-based contrast
agents (GBCAs) in patients with kidney disease is a
particular concern given the risk of nephrogenic systemic
fibrosis (NSF). NSF is a severe systemic disorder that was
recognized in 1997 in patients with kidney dysfunction. To
avoid the development of NSF in patients with kidney
disease, it is necessary to find a safer alternative
contrast medium that provides comparable enhancement to
GBCA.
Iron oxide nanoparticles are potential replacements for
GBCA; they are an alternative blood-brain barrier (BBB)
marker magnetic resonance (MR) contrast agent. These are
promising compounds due to their T1 and T2 relaxation
time shortening effect. Generally, larger molecules have a
different biodistribution from the low-molecular weight
GBCA. Therefore, superparamagnetic iron oxides (SPIOs,
450 nm diameter) with a short plasma half-life were
found less optimal for vascular or central nervous system
(CNS) imaging.1 Ultrasmall superparamagnetic iron oxides
(USPIOs, o50 nm diameter) on the other hand can be used
for contrast-enhanced MR imaging.2,3 (Table 1).
The coating compound and its surface charge are also
major factors that influence the pharmacokinetics and
pharmacodynamics. Consequently, there are major differ-
ences among the various USPIOs. For example, SH U 555C
(Supravist) is a smaller molecule than ferumoxtran-10 (25
versus 30 nm), has a shorter half-life (6–8 versus 24–30 h),
and is negatively charged, resulting in uptake by activated
monocytes in vitro.5 Although SH U 555C was found to be
taken up by circulating cells,6 neither ferumoxtran-10 nor
ferumoxytol were found to do the same.7 SH U 555C
enhancement was found to be independent from BBB
breakdown, and has a more cellular, reticuloendothelial
system-specific enhancement pattern than enhancement from
GBCA.6
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Ultrasmall superparamagnetic iron oxides, such as fer-
umoxytol and ferumoxtran-10, have shown excellent poten-
tial for brain tumor imaging similar to that achieved on
conventional post-GBCA MRI8 because brain tumors
often have an impaired BBB. Current clinical studies have
investigated the newer agent, ferumoxytol, in subjects in
whom contrast-enhanced imaging of CNS lesions may be a
critical step in improving patient management. An advantage
of ferumoxytol is that it has already been tested in patients
with renal failure, unlike agents such as ferumoxtran-10
(USPIO), or the commercially available SPIO, AMI-25
(Feridex). Moreover, ferumoxytol can be safely given as a
short intravenous bolus for MR angiography (MRA) and
dynamic MR where it serves as a true blood pool agent.
Although this article reviews clinical studies with ferumox-
tran-10, it focuses on ferumoxytol as an alternative to GBCA
in patients with kidney failure who require an MR contrast
procedure (Table 2).
CASE EXAMPLE
A 50-year-old male presented with a generalized seizure and
loss of consciousness that occurred while at work. By the time
he reached the emergency department he suffered from
respiratory compromise and was placed on a ventilator.
Subsequently he developed acute kidney injury requiring
dialysis. His serum creatinine in the emergency department
was 1.9 mg/100 ml and rapidly increased to 6 mg/100 ml. A
noncontrast MRI scan demonstrated a brain lesion suspi-
cious for tumor. The decision was made to do a stereotactic
brain biopsy rather than a surgical resection due to the
patient’s compromised state. A GBCA was administered and
the enhancing portion of the lesion was selected as the
stereotactic target. Pathology was anaplastic astrocytoma
grade III/IV. The patient fully recovered neurological and
renal function and is receiving chemo and radiotherapy for a
high-grade glioma (Figure 1).
CAN FERUMOXYTOL HELP THIS PATIENT AND ANALOGOUS
PATIENTS?
Nephrologist view
The association of NSF with GBCA was first reported in 2006,
when five end-stage renal disease patients on hemodialysis
who received GBCA developed NSF 2–4 weeks later. The risk
in end-stage renal disease of developing NSF is estimated to
be 2.4% in dialysis patients after any GBCA exposure, with a
4% prevalence in patients who received gadodiamide, an
agent with a linear nonionic structure and relative ease of Gd
dissociation from its chelate. Patients at risk include those
with stage 4 or 5 chronic kidney disease (CKD; glomerular
filtration rateo30 ml/min per 1.73 m2), acute kidney injury, or
kidney and liver transplant recipients with kidney dysfunc-
tion.14,15 The earliest symptoms include pain and pruritus with
clinical findings of edema, erythema, and warmth most
commonly in the distal, then proximal lower extremities.
Progressive muscle weakness and contractures can occur, along
with cardiac, pulmonary, and scleral involvement.16
Given the complications of GBCA in patients at risk for NSF,
other contrast agents are needed. USPIO nanoparticles have
been used with excellent safety profiles in patients undergoing
hemodialysis.17 If these agents were felt to be safe and gave
equivalent, or superior radiological information, then USPIO
nanoparticles would be an alternative to GBCAs for patients
with kidney dysfunction requiring contrast-enhanced MRI.
As over 200 million patients have been exposed to
GBCA,18 and o300 NSF cases have been diagnosed, the
B1700 ferumoxytol patients to date are too small a number
to accurately evaluate risk of other low-incidence complica-
tions. Although Gd chelates are considered safe, the exception
is in patients with stage 4 or 5 CKD, where there is a slight
but real risk of developing NSF. Thus, ferumoxytol is an
interesting alternative contrast agent to avoid the small, but
potentially fatal risk of NSF in this group of patients. As with
any new drug, rare adverse events remain a risk for
ferumoxytol.
MR physics and chemistry view
Although computed tomography has high spatial resolution,
MRI is the imaging modality of choice when high-resolution
anatomical detail with exceptional soft tissue contrast is
demanded. Indeed, the ability of MRI techniques to generate
exceptional contrast based on intrinsic tissue properties
obviates the need for exogenous contrast media in many
studies. Nevertheless, to increase lesion conspicuity, detect
Table 1 | Superparamagnetic iron oxide MR contrast agents
Short name Generic namea Trade name Signalb Status
Size
(nm)
Bolus
inj. Developer
AMI-227 Ferumoxtran-10 (USPIO) Combidex/sinerem Positive or
negative
Development 30 NO AMAG Pharmaceuticals Inc. (USA)
Guerbet, SA (EU)
AMI-25 Ferumoxides (SPIO) Feridex/endorem Negative For sale 100 NO AMAG Pharmaceuticals Inc. (USA)
Guerbet, SA (EU)
Code 7228 Ferumoxytol (USPIO) Positive Development 30 YES AMAG Pharmaceuticals Inc.
SH U 555 A Ferucarbotran (SPIO) Resovist/cliavist Negative For sale (EU, Australia,
Japan)/development (USA)
62 YES Bayer Schering Pharma AG
SH U 555 C Ferucarbotran (USPIO)4 Supravist Positive Development 25 YES Bayer Schering Pharma AG
NC-100150 PEG-feron (USPIO) Clariscan Positive Development (discontinued) 20 YES Amersham Health
Inj., injection; SPIO, superparamagnetic iron oxides; USPIO, ultrasmall SPIO.
aShort description.
bHigh local concentrations and/or appropriate pulse sequence parameters, negative contrast can be achieved (e.g., first-track bolus); (modified from http://www.emrf.org/
and http://www.mr-tip.com/).
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inflammation, improve vascular characterization, or demon-
strate angiogenesis, MRI contrast agents are frequently used.
It has been estimated that up to 40% of all MRI studies are
now acquired using contrast media.
The five FDA-approved MRI contrast agents are based on
the Gd(III) ion, which has excellent potency to catalyze the
relaxation of the MRI water signal due to its seven unpaired
electrons and favorable electronic relaxation times.19 To
improve safety and pharmacokinetics, the Gd(III) ion must
be chelated to an appropriate ligand, typically a low-
molecular weight organic molecule. The archetypical ligand
is DTPA5 (diethylenetriaminepentaacetate) that forms a
very strong chelate with Gd(III). Tight binding of Gd by the
chelate is important as both the free Gd and ligand are
potentially toxic. In 1988, GdDTPA2 became the first FDA-
approved MRI contrast agent. Since then four other low-
molecular weight monomeric chelates of Gd(III) have gained
FDA approval, each with unique biophysical properties. All
approved GBCAs are administered intravenously, distribute
into accessible extracellular spaces with a distribution half-life
of B10 min, and are eliminated through the kidneys with a
plasma half-life typically of B90 min in healthy human
adults19 (Table 2). If kidney function is impaired, contrast
agent plasma elimination can be markedly prolonged, with a
half-life that may exceed 30 h in some individuals.20
Neuroradiology view
GBCA-enhanced MRI scans remain essential in numerous
common clinical settings, including cerebritis, encephalitis,
ventriculitis, demyelinating disease, subacute infarcts, lepto-
meningeal disease (infection and carcinomatous), character-
ization of primary and secondary CNS neoplasms, and for
differentiating tumors from vascular malformations. In some
cases, Gd enhancement will be the only diagnostic feature of
the lesion, thus underscoring its importance. Correct imaging
Table 2 | Ferumoxtran-10 (Combidex), Ferumoxytol, and Gd-DTPA (Magnevist)a
Feature Ferumoxtran-10 (Combidex) Ferumoxytol Gd-DTPA (Magnevist)
Basic element Iron9 Iron oxide Gadolinium(III)
Molecular composition Iron oxide coated with dextran9 Iron oxide coated with
semisynthetic carbohydrate
Gadolinium chelated with
diethylenetriamine pentaacetic
acid
r1 (mmol/s) at 0.47 T, 39 1C 23
9 3810 3.4
r2 (mmol/s) at 0.47 T, 39 1C 53
9 8310 4
Elimination plasma half-life 24–30 h9 14 h11 1.6 h
Relative size of the particle Around 30 nm9 Around 30 nm11 0.357 nm
Permeability to intact BBB Minimal Minimal Minimal
Clinical significance of the
enhancing area
Imaging sites of BBB
abnormality mainly in the
presence of inflammatory cells
Imaging sites of BBB
abnormality mainly in the
presence of inflammatory cells
Detects abnormality in BBB and
abnormal vascularity
Typical times to peak
enhancement in brain tumors
24–72 h1 24 h3 3.5–25 min
Signal change on T1-weighted
sequence
High signal at low
concentrations, low signal at
higher concentrations12
High signal at low
concentrations, low signal at
higher concentrations
High signal
Signal change on T2-weighted
sequence
Low signal Low signal Slightly low signal
Distribution Initially a blood pool agent and
then intracellular in
macrophages and reactive
astrocytes
Initially a blood pool agent and
then intracellular in
macrophages and reactive
astrocytes
Extracellular
Imaging dose 2.6 mg of Fe/kg diluted in
100 ml (infusion)
1–4 mg/kg 0.2–0.6 ml/kg (0.1–0.3 mmol/kg)
Rate of administration Infused over 30 min Bolus 10 ml/min or as bolus at
10 ml/15 s
Excretion Stored with the body’s iron
reserve and used in hemopoesis
Stored with the body’s iron
reserve and used in hemopoesis
Renal
BBB, blood-brain barrier.
aThe table shows the relevant features of the two contrast agents used in this study (modified from Murillo et al.13). There are differences in size, half-lives, clinical significance
of the enhanced areas, distribution (plasma half-life), and side effects. GBCAs have excellent safety profiles in individuals with normal renal function and can be given in
multiple doses. Ferumoxtran-10 is given slowly to avoid pseudoallergic reactions. Ferumoxytol can be administered as a bolus. A particle of ferumoxtran-10 or ferumoxytol is
almost 100 larger than a GBCA.
Figure 1 | Patient who presented to the Emergency
Department comatose in acute renal failure with a large
cerebral hemispheric mass. Axial T1-weighted MR scan without
(left) and with (right) Gd 24 h post-admission when serum Cr was
6.0 mg/100 ml.
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diagnosis frequently alters clinical management, and is often
dependent on analysis of enhancement patterns.
Contrast agents are highly desirable for evaluating
intracranial neoplasms, as in the current case example
(Figure 1), for several reasons. These include:
(1) Differentiating metastatic versus glial origin tumors.
Metastatic disease in particular can be punctate or
leptomeningeal in nature. Such lesions may only be
identified with a contrast-enhanced MR study. Even
contrast-enhanced computed tomography can miss these
subtle types of tumor spread.
(2) Enhancement usually suggests higher grade tumor, but is
also useful in directing biopsy to the ‘highest yield’ site of
tumor, thereby improving the likelihood of obtaining the
highest grade portion of tumor for histologic analysis.
(3) Contrast enhancement is useful on baseline studies to
assist in future imaging follow-up because certain tumors
would strongly be expected to enhance if recurrent, for
example primitive neuroectodermal tumors or lympho-
ma. By contrast low-grade glial tumors may demonstrate
recurrence by increasing T2 signal abnormality without
enhancement, and new enhancement suggests the
possibility of conversion of low-grade gliomas into a
higher grade lesion such as glioblastoma multiforme.
(4) Contrast enhancement patterns are occasionally helpful
in clarifying cases of tumefactive multiple sclerosis that
are better treated conservatively or diagnosed with
confirmatory biopsy rather than attempting ‘gross total
resection’ that may result in unnecessary deficits for
patients.
Neurosurgical view
Enhanced preoperative MRI using conventional stereotactic
and intraoperative MRI for brain biopsies and/or resection
requires contrast. USPIO nanoparticles have a long
plasma half-life and are trapped by reactive cells within the
tumor. These trapped particles provide a method to
demonstrate enhancing lesions without the artifact of
repeat GBCA administration in the face of BBB and
vascular injury due to surgery. USPIO particles represent a
method to demonstrate enhancing intrinsic brain tumors
without the drawbacks of intraoperative Gd enhancement.
These lesions appear even on low-field strength intraopera-
tive MRI.1,8,21 Ferumoxtran-10 and ferumoxytol, adminis-
tered preoperatively, provides a stable imaging marker, even
after surgical manipulation of the brain. However, it should
be recognized that after crossing the impaired BBB, the
distribution of iron oxides is fundamentally different from
Gd chelates. Whereas USPIOs are taken up by phagocytic
cells, Gd chelates distribute in the interstitial extracellular
space (Figure 2). Furthermore, unlike SH U 555C, ferumox-
ytol is not taken up by circulating mononuclear cells, thereby
making it more of a BBB marker than a marker for
inflammation.6 However, after crossing the BBB, ferumoxytol
is taken up by phagocytic cells.7
Another imaging option is computed tomography scan-
ning using iodinated contrast, but again, in patients with
renal compromise, iodinated contrast has risk and computed
tomography has less spatial resolution in soft tissue than MR.
In our experience to date, all biopsies from tumors that
enhance with USPIO have contained tumor cells.
SAFETY AND PRELIMINARY STUDIES WITH FERUMOXYTOL
VERSUS OTHER IRON REPLACEMENT AND IMAGING AGENTS
Some iron oxide agents, such as Feridex and ferumoxtran-10,
require slow infusion of relatively low doses to avoid
adverse reactions, making them unsuitable for vascular
applications, whereas ferumoxytol appears to have fewer
systemic reactions and can be given as a bolus for MRA
BBB
Gd
L
Fe
L
BBB
Figure 2 | Schematic distribution comparing Gd versus USPIO crossing the BBB to tumor. (a) Shows Gd chelates (abbreviated Gd in the
figure) crossing from the intravascular compartment through a defective BBB (arrow) to the interstitial space. GBCA, which vary in
propensity to release Gd, and thereby possibly risk of NSF (see text), remains in the extracellular space at the time of imaging (minutes after
infusion). Macrophages, reactive astrocytes are shown around the lesion (L) but GBCA does not enter these cells. During its short half-life
(less than 1 h), Gd rapidly crosses the BBB to produce a hyperintense signal on T1-weighted sequence on MR. In CKD, Gd-chelated contrast
is not cleared rapidly and can be demonstrated in tissues.22 (b) Ferumoxtran-10 (Fe in black) and other ultra small iron oxides are much
larger particles compared to GBCAs; these particles will slowly cross the defective BBB (arrow). Due to its prolonged half-life of 25–30 h
particles of ferumoxtran-10 will progressively accumulate in the interstitial space where they will be trapped by reactive astrocytes and
macrophages for days (up to 7 days). The intracellular metabolism of ferumoxtran-10 will take place in the lysosome of these cells where
free iron will be released to the extracelullar space. Reactive astrocytes, macrophages, and other inflammatory cell are seen in different
diseases affecting the CNS, among these stroke, neoplasm, and demyelinating processes. Figure modified from Murillo et al.13 (reproduced
with permission of Expert Reviews Ltd).
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analysis of vasculature.23,11 Even so, with inflammatory
lesions ferumoxtran-10 may have a slight advantage for
anatomic imaging.
Ferumoxytol was developed as an intravenous iron-
replacement therapy, specifically for anemic patients with
CKD including those on dialysis. It has not yet been
approved by the FDA for marketing but a New Drug
Application was submitted in December 2007.
Following an infusion of iron in healthy individuals,
dietary absorption of iron decreases, whereas in CKD
patients, iron stores are depleted. In either case, attention
to the potential of oxidative stress needs to be considered,
although to date, no such toxicity has been seen in either
normal individuals or CKD patients.
Over 1700 patients have been exposed to ferumoxytol in
its clinical development program, and at least 1500 of these
were patients with CKD in Phase 3 iron-replacement studies.
To date, only one patient, (with a history of multiple drug
allergies) has experienced an anaphylactoid reaction (hot
flashes and itching, with no respiratory compromise) and
severe hypotension a few minutes after receiving ferumox-
ytol. There have been no deaths that were considered to be
related to ferumoxytol treatment.
The other intravenously administered iron-replacement
therapies contain only paramagnetic iron, which would
preclude safe administration in sufficient doses to provide
adequate MR contrast.
Currently, there are no other iron oxide particles showing
both safety in CKD, and in angiographic imaging. Although
SH U 555A (Resovist) is approved in Europe, it is not
approved in the United States, and furthermore has not been
tested in CKD; this is also true for another USPIO called SH
U 555C (Supravist).6,4 Mn-DPDP (Teslascan), a manganese
contrast agent, is approved in the United States, although not
marketed, and to our knowledge has not been evaluated in
CKD. Thus, ferumoxytol is the only USPIO agent used for
MRA and anatomic CNS imaging that to date has a safe track
record in patients with kidney disease (Table 1).6,4,24
CLINICAL STUDIES
MR imaging with a nanoparticle magnetic resonance contrast
agent
As compared with USPIO, MRI of the CNS carried out with
Gd-containing contrast agents is based on low-molecular
weight extracellular-chelated agents with a short half-life,
giving rapid and transient imaging of brain and spinal cord
permeability.13 USPIO nanoparticle MR contrast agents have
shown excellent potential for imaging in the CNS. (Table 1)
The agents consist of an iron oxide core with a variable
coating that determines cellular uptake and biological half-
life. In the CNS, ferumoxtran-10 has been most widely
investigated in brain tumors.1 It is completely coated with
native dextran, which protects against opsonization and
endocytosis, and bestows a long plasma half-life of 24–30 h.
Ferumoxtram-10
EM
Histochemistry
Gadolinium
Patient with GBMRat brain tumor
No contrast
Ferumoxtran-10
T
T
Figure 3 | Nanoimaging: from bench to bedside. (a) Rat brain tumor before and after USPIO MR contrast. (b) Post-GBCA T1-weighted
MRI shows a large left frontoparietal-enhancing tumor (arrows). At 24 h post–ferumoxtran, T1-weighted MRI shows intense enhancement
in the left frontoparietal tumor (arrows) and a new lesion medial to the main tumor mass in the putamen (arrowhead). Cellular iron
staining at the tumor–reactive brain interface shows iron uptake by the parenchymal cells with fibrillar processes (arrows) rather than by
the round tumor cells (T). EM shows electron dense core of USPIO.1 (Reproduced from AJNR Am J Neuroradiol 2002; 23:510–519 with
permission of Lippincott, Williams & Wilkins, 2008.)
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On MR scans, the iron oxide agents demonstrate concentra-
tion related signal loss on T2- and T2*-weighted sequences.
Lower concentrations of USPIO on T1-weighted sequences
increase signal intensities, similar to that seen on Gd
enhancement; higher concentrations of USPIO can cause
profound signal loss on T1-weighted images due to extreme
T2* shortening.12 In addition, iron oxide particles can be
identified at the light and electron microscopic levels
(Figure 3),1 allowing evaluation of their exact location within
tissues,12 unlike other CNS MRI agents.
Clinical trials using ferumoxtran-10 to image brain tumors
Ultrasmall superparamagnetic iron oxide agents have shown
promise in clinical trials for tumor imaging, both systemi-
cally and in the brain. They can be useful in differentiating
between malignant and benign lymph nodes, as well as in
MRA and perfusion imaging of the brain, heart, and trunk
vessels.23 In reactive brain lesions, the iron oxide agents may
detect active inflammatory or demyelinating lesions6 after
iron uptake in perivascular macrophages.25 More recently,
several studies have looked at ferumoxtran-10-enhanced MR
imaging of brain tumors. Early studies demonstrated the
prolonged enhancement of brain tumors after USPIO
administration when compared to standard Gd. Delayed
MRI (24–48 h) following administration of ferumoxtran-10
has been reported to show additional areas of enhancement
in brain tumors that were not seen with Gd (Figure 3),1
particularly in areas where reactive inflammatory cells were
present.1,8 Prolonged enhancement of brain tumors (up to 7
days) in patients was associated with progressive accumula-
tion of ferumoxtran-10 in reactive astrocytes and macro-
phages rather than tumor cells.1,8 In a subsequent study,
ferumoxtran-10 was compared to Gd-enhanced MR to assess
its potential in evaluation of a variety of CNS lesions.2
Ferumoxtran-10 showed different enhancement patterns in a
variety of CNS inflammatory lesions in comparison to Gd
(Figure 4). In particular, some cases of lymphomas
and ischemic lesions demonstrated stronger enhancement
(Figure 5).2 These observations and preclinical data suggest
that ferumoxtran-10 enhanced MR, in addition to the usual
Gd-enhanced MR, may identify those part(s) of the lesion
that contain both reactive inflammatory changes and a BBB
defect, thereby helping differentiate portions of a lesion with
and without inflammatory reaction. This may have implica-
tions for targeting of diagnostic biopsies and the planning of
surgical resections.
CoronalCoronal
10/14/03 10/20/03 2/4/0410/14/03
T1 T1 Ferumoxtran-10 T1 Gadolinium T1 Gadolinium
Figure 4 | Patient with acute disseminated encephalomyelitis (ADEM). Axial T1-weighted MRI images without (a) and with (b) GBCA
show faint, subtle enhancement in multiple brainstem lesions. At 6 days later (c) significant, more prominent, larger ferumoxtran-10
enhancement can be seen on the same site. At 3 months later (d), the lesions no longer enhance on T1-weighted images with GBCA.2
(Reproduced from AJNR Am J Neuroradiol 2005; 26:2290–2300 with permission of Lippincott, Williams & Wilkins, 2008).
9/6/03 9/16/03 12/15/039/6/03
T1 T1 Ferumoxtran-10 T1 Gadolinium T1 Gadolinium
Figure 5 | Patient with Stroke. Axial T1-weighted MRI without (a) and with (b) GBCA show no significant enhancement in left insular
cortex, basal ganglia, and frontoparietal lobe where DWI, T2, and FLAIR images showed high intensity (not shown) consistent with acute
MCA infarction. At 10 days later, T1 images with ferumoxtran-10 (c) show significant enhancement in the same region. At 90 days later (d),
axial T1-weighted image after GBCA shows no enhancement.2 (Reproduced from AJNR Am J Neuroradiol 2005; 26:2290–2300 with
permission of Lippincott, Williams & Wilkins, 2008).
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CNS imaging with ferumoxytol
The main difference between ferumoxytol and ferumoxtran-
10 is the coating. Ferumoxytol is not dextran coated, and the
modified carbohydrate design makes ferumoxytol better
tolerated for bolus injections. Because of this modification
and the fact that USPIO particles can serve as blood pool
agents. Ferumoxytol may be used for MRA and perfusion of
the brain and other organs. Ferumoxytol was supplied by
AMAG Pharmaceuticals Inc. (Cambridge, MA, USA).
Ferumoxytol can be used at early time points (seconds to
minutes) to image the vasculature by MRA without the rapid
extravasation into CNS lesions that limit MRA with Gd-based
contrast agents (Table 2). USPIOs such as ferumoxytol, even
in the presence of transfecting agents (unlike superparamag-
netic iron oxides (SPIOs)) do not enter circulating phago-
cytic cells (Figure 6). These properties make ferumoxytol a
promising agent in neurological diagnosis and neurosurgery
in malignant gliomas (Figure 7).3 Ferumoxytol enhancement
likely represents an inflammatory reaction with BBB leaki-
ness, due to both a BBB abnormality and presence of
phagocytic cells. As with ferumoxtran-10, the time to peak
enhancement of ferumoxytol on T1-weighted MRI is
typically around 24 h and lasts at least 72 h after administra-
tion. It may be useful in surgical interventions for malignant
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Figure 6 | Ferumoxides but not ferumoxtran-10 nor ferumoxytol (even in the presence of protamine sulfate) label circulating rat
mononuclear cells after intravenous infusion. Female Long Evans rats received IV ferumoxides, ferumoxtran-10, or ferumoxytol
(20 mg/kg) with or without preincubation with protamine sulfate (Pro) (2 mg/kg). (a) Mononuclear cells were isolated from peripheral
circulation 2 h after injection and stained with DAB-enhanced Perl’s blue. Iron-labeled cells with brown stain are indicated by arrowheads.
(b) Percentage of iron-positive-stained cells in total mononuclear cell population. (c) Time course of ferumoxide-Pro in vivo iron-labeled rat
mononuclear cells. Data are represented as mean±s.e.m.7 (Used with permission from Am J Physiol Cell Physiol 2007; 293: C1698–C1708).
Figure 7 | Gd versus ferumoxytol MR pre-operatively and
intra-operatively in a glioma patient using a 3 T versus a 0.15
T magnet. Glioma patient (a) T1-enhancement with GBCA. At 24 h
after ferumoxytol infusion, (b) T1 enhancement, (c) T2*-weighted
images. (d) Intraoperative T1-weighted 0.15 T MR 26 h after
ferumoxytol injection.3 (Reproduced from Neurosurgery 2007; 60:
601–611; discussion 611–602, with permission of Lippincott,
Williams & Wilkins, 2008).
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tumors in two ways. First, image guided neurosurgery or
stereotactic biopsy may be better directed with the informa-
tion provided by USPIOs such as ferumoxytol. Second, if
gross resection is performed, the prolonged enhancement (up
to 7 days) can aid intra- and postoperative assessment by MR
during or after surgery without further administration of the
contrast agent.21
Vascular enhancement with ferumoxytol for dynamic MR in
the CNS
Although GBCA imaging relies on rapid crossing of the
impaired BBB for anatomic imaging studies, it may be a
limitation in performing dynamic studies of the vasculature
in areas of abnormal BBB permeability. An agent that rapidly
leaves the capillaries (Figure 8)3 may confound perfusion
(blood volume and flow) measurements, whereas an agent
like ferumoxytol, that leaves the vasculature slowly, provides
more accurate measurements of perfusion in areas of leaky
BBB at early time points as it then acts as a blood pool agent
(Figure 9).26 Inflammation at the BBB is a fundamental
component of CNS pathology in brain tumors as well as CNS
injury from trauma or multiple sclerosis. Ferumoxytol does
not leak out of blood vessels in the early phase after injection
(i.e. is a blood pool agent) and therefore is excellent for
dynamic MR perfusion and angiography.
Due to its prolonged half-life at later time points,
ferumoxytol provides anatomic images of brain and also
can be used for steady-state angiography (Figure 10).
Vascular enhancement with ferumoxytol MRA outside CNS
First-pass and equilibrium phase MRA have been performed
using ferumoxytol in 11 healthy volunteers, 6 stent graft
patients,23 and 9 deep vein thrombosis patients. The
examined vessels included carotid arteries, thoracic aorta,
abdominal aorta, and peripheral arteries. First-pass MRA
showed selective arterial enhancement, with both arterial and
venous enhancement on delayed acquisitions. Selective
venous enhancement could be obtained by subtraction of
arterial phase images from equilibrium phase images. With
ferumoxytol, arteries and veins can be selectively depicted in
a b c
Figure 8 | Time of Flight Angiography in a patient with glioblastoma. (a) Without contrast. (b) At 15 min after GBCA, more vessels
are visible. There is an early leak into the left frontal tumor. (c) At 15 min post-ferumoxytol infusion, more vessels are visible, but there is no
leak into the tumor.3 (Reproduced from Neurosurgery 2007; 60: 601–611; discussion 611–602 with permission of Lippincott, Williams &
Wilkins, 2008).
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Figure 9 | Perfusion MR, time-intensity curves in a patient with pineal blastoma. (a) Using GBCA, leakage of the contrast agent
decreases the slope of the recovery curve in the tumor. (b) Ferumoxytol signal intensity curves show no leakage in the lesion.3 (Reproduced
from Neurosurgery 2007; 60: 601–611; discussion 611–602 with permission of Lippincott, Williams & Wilkins, 2008).
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a single exam. Ferumoxytol may be very useful in assessing
the aorta and peripheral arteries of renal patients who
often have diabetes and/or hypertension with major arterial
pathology. Figure 11 is a postrenal transplant MRA with
ferumoxytol showing aortic aneurysm, iliac artery stent,
transplanted kidney, and polycystic kidney all in same
patient.27
CONCLUSION
Patients with kidney disease as defined above are at risk for
NSF if given GBCAs. NSF is not common but can be severely
debilitating and potentially fatal. USPIOs being developed for
iron-replacement therapy primarily in patients with kidney
disease, have excellent potential as MRI contrast agents.
However, the distribution of USPIO and GBCA is different,
with the former largely distributing into the reticuloendo-
thelial system and blood pool, whereas the latter distributes
into the extracellular space after a relatively short residence
within the blood pool. To date, preclinical and clinical
studies suggest excellent potential for USPIOs such as
ferumoxytol as an alternative to GBCA in patients at risk
for NSF, not only for anatomic imaging, but also for MRA
and dynamic MRI.
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